CONTEXT: Adiponectin has been suggested to play a role in the etiopathogenesis of at least some forms of insulin resistance, in part based on a strong correlation between plasma levels of adiponectin and measures of insulin sensitivity. OBJECTIVE: The objective of the study was to establish whether this relationship is maintained at extreme levels of insulin resistance. DESIGN/ SETTING: This was a cross-sectional study in a university teaching hospital of subjects recruited from the United Kingdom and the United States. PARTICIPANTS: Participants included 75 subjects with a range of syndromes of severe insulin resistance and 872 nondiabetic controls. OUTCOME MEASURES: Fasting plasma insulin, adiponectin, and leptin were measured. RESULTS: Unexpectedly, subjects with mutations in the insulin receptor, despite having the most severe degree of insulin resistance, had elevated plasma adiponectin [median 24.4 mg/liter; range 6.6-36.6 (normal adult range for body mass index 20 kg/m(2) = 3-19 mg/liter)], whereas all other subjects had low adiponectin levels (median 2.0 mg/liter; range 0.12-11.2). Plasma leptin in all but one subject with an insulin receptoropathy was low or undetectable [median 0.5 ng/ml; range 0-16: normal adult range for body mass index of < 25 kg/m(2) = 2.4-24.4 (female) and 0.4-8.3 ng/ml (male)]. CONCLUSIONS: We conclude that the relationship between plasma adiponectin and insulin sensitivity is complex and dependent on the precise etiology of defective insulin action and that the combination of high plasma adiponectin with low leptin may have clinical utility in patients with severe insulin resistance as a marker of the presence of a genetic defect in the insulin receptor.
CONTEXT: Adiponectin has been suggested to play a role in the etiopathogenesis of at least some forms of insulin resistance, in part based on a strong correlation between plasma levels of adiponectin and measures of insulin sensitivity. OBJECTIVE: The objective of the study was to establish whether this relationship is maintained at extreme levels of insulin resistance. DESIGN/ SETTING: This was a cross-sectional study in a university teaching hospital of subjects recruited from the United Kingdom and the United States. PARTICIPANTS: Participants included 75 subjects with a range of syndromes of severe insulin resistance and 872 nondiabetic controls. OUTCOME MEASURES: Fasting plasma insulin, adiponectin, and leptin were measured. RESULTS: Unexpectedly, subjects with mutations in the insulin receptor, despite having the most severe degree of insulin resistance, had elevated plasma adiponectin [median 24.4 mg/liter; range 6.6-36.6 (normal adult range for body mass index 20 kg/m(2) = 3-19 mg/liter)], whereas all other subjects had low adiponectin levels (median 2.0 mg/liter; range 0.12-11.2). Plasma leptin in all but one subject with an insulin receptoropathy was low or undetectable [median 0.5 ng/ml; range 0-16: normal adult range for body mass index of < 25 kg/m(2) = 2.4-24.4 (female) and 0.4-8.3 ng/ml (male)]. CONCLUSIONS: We conclude that the relationship between plasma adiponectin and insulin sensitivity is complex and dependent on the precise etiology of defective insulin action and that the combination of high plasma adiponectin with low leptin may have clinical utility in patients with severe insulin resistance as a marker of the presence of a genetic defect in the insulin receptor.
Authors: R Malek; A Y Chong; B C Lupsa; A O Lungu; E K Cochran; M A Soos; R K Semple; J E Balow; P Gorden Journal: J Clin Endocrinol Metab Date: 2010-05-19 Impact factor: 5.958
Authors: Marie H Solheim; Jonathon N Winnay; Thiago M Batista; Anders Molven; Pål R Njølstad; C Ronald Kahn Journal: Diabetes Date: 2018-05-03 Impact factor: 9.461
Authors: Linda Koch; F Thomas Wunderlich; Jost Seibler; A Christine Könner; Brigitte Hampel; Sigrid Irlenbusch; Georg Brabant; C Ronald Kahn; Frieder Schwenk; Jens C Brüning Journal: J Clin Invest Date: 2008-06 Impact factor: 14.808
Authors: J Brent Richards; Dawn Waterworth; Stephen O'Rahilly; Marie-France Hivert; Ruth J F Loos; John R B Perry; Toshiko Tanaka; Nicholas John Timpson; Robert K Semple; Nicole Soranzo; Kijoung Song; Nuno Rocha; Elin Grundberg; Josée Dupuis; Jose C Florez; Claudia Langenberg; Inga Prokopenko; Richa Saxena; Robert Sladek; Yurii Aulchenko; David Evans; Gerard Waeber; Jeanette Erdmann; Mary-Susan Burnett; Naveed Sattar; Joseph Devaney; Christina Willenborg; Aroon Hingorani; Jaquelin C M Witteman; Peter Vollenweider; Beate Glaser; Christian Hengstenberg; Luigi Ferrucci; David Melzer; Klaus Stark; John Deanfield; Janina Winogradow; Martina Grassl; Alistair S Hall; Josephine M Egan; John R Thompson; Sally L Ricketts; Inke R König; Wibke Reinhard; Scott Grundy; H-Erich Wichmann; Phil Barter; Robert Mahley; Y Antero Kesaniemi; Daniel J Rader; Muredach P Reilly; Stephen E Epstein; Alexandre F R Stewart; Cornelia M Van Duijn; Heribert Schunkert; Keith Burling; Panos Deloukas; Tomi Pastinen; Nilesh J Samani; Ruth McPherson; George Davey Smith; Timothy M Frayling; Nicholas J Wareham; James B Meigs; Vincent Mooser; Tim D Spector Journal: PLoS Genet Date: 2009-12-11 Impact factor: 5.917
Authors: Sara G I Suliman; Juraj Stanik; Laura J McCulloch; Natalie Wilson; Emma L Edghill; Nadezda Misovicova; Daniela Gasperikova; Vilja Sandrikova; Katherine S Elliott; Lubomir Barak; Sian Ellard; Emanuela V Volpi; Iwar Klimes; Anna L Gloyn Journal: Diabetes Date: 2009-08-31 Impact factor: 9.461
Authors: F M Finucane; J Luan; N J Wareham; S J Sharp; S O'Rahilly; B Balkau; A Flyvbjerg; M Walker; K Højlund; J J Nolan; D B Savage Journal: Diabetologia Date: 2009-09-12 Impact factor: 10.122